BioSpace News Archive

Business

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Carisma Therapeutics Inc. announced Robert Petit, Ph.D., as its Chief Scientific Officer.

June 3, 2019
·
2 min read
Business

Lyndra Therapeutics Welcomes Dr. Patricia Hurter as Chief Executive Officer

Addition to management team strengthens Lyndra’s development capabilities

June 3, 2019
·
3 min read
Policy

Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Reviva Pharmaceuticals, Inc. announced that it has successfully completed a pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis.

June 3, 2019
·
4 min read
Drug Development

Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies

Genentech, a member of the Roche Group, announced positive topline data from two Phase III multicenter studies evaluating Xolair® for the treatment of adults with chronic rhinosinusitis with nasal polyps who have not adequately responded to intranasal corticosteroids.

June 3, 2019
·
9 min read
Policy

Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL

Nordic Nanovector ASA announces that the European Patent Organisation has granted the company’s European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin’s lymphoma.

June 3, 2019
·
4 min read
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

June 3, 2019
·
2 min read
Drug Development

Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation

June 3, 2019
·
12 min read
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination - June 3, 2019

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

June 3, 2019
·
2 min read
Sensorion Announces Poster Presentation at the “Société Internationale d’Otoneurologie” Symposium

Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV)

June 3, 2019
·
3 min read
Drug Development

New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib

Incyte announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.

June 3, 2019
·
7 min read